Objective: The purpose of this study was to specifically investigate the clinicopathological role of expression of vascular endothelial growth factor-C (VEGF-C) as well as the correlation with clinical outcomes in esophageal squamous cell carcinomas (ESCCs). Methods: Seventy-three patients with ESCC resected in our institute were included in this study. Formalin-fixed paraffin-embedded specimens were stained for VEGF-C and the correlation between the staining, its clinicopathological parameters and its prognostic power were analyzed statistically. Results: Of the 73 ESCC patients studied, 39 cases (53.4%) were strongly positive for VEGF-C. Six cases (8.2%) were negative and 28 cases (38.4%) revealed unclear weak reactions. All 34 cases were included in the negative group (46.6%). VEGF-C expression correlated with histological grade (P ¼ 0.005), depth of tumor invasion ( pT) (P ¼ 0.021), lymph node metastasis ( pN) (P ¼ 0.002) and lymphatic invasion (P ¼ 0.008). The median overall survival of 39 patients who had positive staining for tumor cell VEGF-C and 34 patients who had negative staining were 10.4 months (95% CI, 6.9 -13.9 months) and 28.5 months (95% CI, 12.6 -44.4 months), respectively (P ¼ 0.003). In univariate analysis by log-rank test, histological grade, pN, stage, lymphatic invasion and VEGF-C were significant prognostic factors (P ¼ 0.047, 0.007, 0.018, 0.002 and 0.003, respectively.). In multivariate analysis, high VEGF-C expression (P ¼ 0.0451) maintained its independent prognostic influence on overall survival, as well as pN status (P ¼ 0.0029). Conclusions: Expression of VEGF-C is related to histological grade, pT, pN and lymphatic invasion, and is a prognostic indicator for ESCC.
INTRODUCTION
Esophageal squamous cell carcinoma (ESCC) is one of the deadliest malignancies worldwide. Late recognition of more than half of the ESCC cases, when curative resection of the tumor is not possible or distant metastases are already present, greatly contributes to low survival rates. However, up to date, no biomarkers of ESCC have been proposed (1) . Most of the cancers spread primarily by the means of lymphatic vessels. Yet, it remains controversial whether a spread of cancer cells via lymphatic system requires the development of new vessels, similarly to tumor angiogenesis (2) . The presence and the number of metastatic lymph nodes are significant prognostic factors and largely decide on the extension of curative resection in ESCC. Metastases in lymph nodes, occult or overlooked during surgery, are responsible for disease recurrence and patient's death even in locally not advanced cancers. However, despite new imaging techniques, the sensitivity and specificity of clinical evaluation of lymph node involvement remains unsatisfactory (3) .
Vascular endothelial growth factor-C (VEGF-C), a member of the VEGF family, specifically activates the VEGF receptor-3 (VEGFR-3), a cell surface tyrosine kinase receptor expressed on lymphatic endothelial cells (4, 5) as well as on other cell types such as cancer cells (6 -8) .
Various authors have reported VEGF-C expression using immunohistochemical staining or reverse transcription polymerase chain reaction in various cancers of the central nervous system (9,10), head and neck (11) , thyroid (12, 13) , lung (14 -16) , breast (17) , stomach (18 -21) , large bowel (7, 22) , uterus (23, 24) , prostate (25) and esophageal cancer (26, 27) . In previous studies, it has been found that VEGF-C expression correlated with depth of tumor invasion ( pT) (26,28 -33) , tumor stage (26, 30, 32, 34) , venous invasion (26) , lymphatic invasion (26, 28, 31, 33, 34) , lymph node metastasis ( pN) (26,28 -33,35,36) , and histological grade (37) in esophageal cancer. However, the prognostic significance of VEGF-C status remains controversial, there was only one published study that confirmed the prognostic value of VEGF-C in esophageal cancer by multivariate analysis. Thus, the present study was designed to specifically investigate the clinicopathological role of expression of VEGF-C, as well as the correlation with clinical outcomes in ESCC.
PATIENTS AND METHODS

PATIENTS AND TISSUES
Surgical specimens were collected from 73 patients with primary ESCC and who underwent radical esophagectomy without pre-operative chemoradiotherapy from January 2002 and December 2008 at Gastrointestinal Center, Jiangyin People's Hospital, Medical School of University of Southeast of China (Jiangyin, People's Republic of China). All the patients received post-operative adjuvant chemotherapy of 5-fluorouracil plus cisplatin regimen. The patients were 56 males and 17 females, whose median age was 61 years (range, 33 -78 years). Eighteen patients had the earlystage disease (24.7%) and 40 patients had lymph node metastases (54.8%). The median follow-up period was 21.5 months. The clinicopathologic stage was determined according to the TNM classification system of the International Union Against Cancer (UICC) (38) . This study was carried out in accordance with the principles embodied in the Declaration of Helsinki, 1975, and informed consent for the usage of esophageal tissues was obtained from each patient.
IMMUNOHISTOCHEMISTRY
Antibodies against VEGF-C were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibody is an affinity-purified goat polyclonal antibody raised against a peptide corresponding to amino acids 136 -155 mapping at the COOH terminus of the VEGF-C of human origin. For the immunohistochemical study, paraffin sections 2 mm thick were deparaffinized and heat treated with citrate buffer, pH 6.0, for 7 min as an epitope retrieval protocol. Endogenous peroxidase was blocked with 3% hydrogen peroxide for 7 min at room temperature, and tissue non-specific-binding sites were blocked with skimmed milk powder at 4% applied for 30 min. Sections were then incubated with the antibody for 1 h (dilution 1:50 for VEGF-C) and mixed with skimmed milk powder at 2% again to reduce unspecific staining. Then they were reacted with biotinylated secondary antibody for 30 min, avidin -biotin -peroxidase complex (Dako LSAB2 system, DAKO Co., Carpinteria, CA, USA) was added and color was developed using 3-3 0 -diaminobenzidine. Counterstaining was done with hematoxylin. All steps were performed at room temperature. Fetal lung tissue was used as a positive control, and omitting the primary antibody from the procedure on the protocol was used as a negative control.
EVALUATION OF VEGF-C IMMUNOLABELING IN CANCER CELLS
The labeling intensity using a three-stage scale (score 0 -2; 0, no staining or equivocal immunoreactions; 1, faint; 2, moderate or marked stainings) and the percentage of positive tumor cells were evaluated under double-blind conditions (Dr P.L. and B.L.) without knowledge of clinical or pathological data. A tumor was defined as significantly positive for VEGF-C expression when a labeling score of 1 was observed in at least 50% of tumor cells or a labeling score of 2 or 3 was observed in at least 30% of tumor cells.
STATISTICAL ANALYSIS
Correlation between VEGF-C expression and clinicopathological factors was analyzed using Fisher's exact probability test or x 2 test. Univariate analysis was performed by modeling Kaplan -Meier survival curves. The log-rank test was used to evaluate the statistical significance of differences in survival distributions among prognostic groups. Multivariate analysis was carried out by the use of the Cox proportional hazard model. A P-value of ,0.05 was considered to be significant. The statistical data were obtained using an SPSS software package (SPSS 11.5 Inc., Chicago, IL, USA). 
RESULTS
RELATION OF CLINICOPATHOLOGIC FACTORS ACCORDING TO VEGF-C EXPRESSION
In cancer cells, it was generally the cytoplasm that revealed various intensity of positive reaction for VEGF-C (Fig. 1) .
There was no heterogeneity of VEGF-C immunoreactivity within the single esophageal cancer tissue. Of the 73 ESCC patients studied, 39 cases (53.4%) were strongly positive for VEGF-C. Six cases (8.2%) were negative and 28 cases (38.4%) revealed unclear weak reactions, the 34 cases were included in the negative group (46.6%). The relationship between VEGF-C expression and clinicopathological features is shown in Table 1 . VEGF-C expression correlated with histological grade (P ¼ 0.005), pT (P ¼ 0.021), pN (P ¼ 0.002) and lymphatic invasion (P ¼ 0.008). No other clinicopathological parameter was related to VEGF-C expression (Table 1) .
RELATION OF THE FACTORS TO SURVIVAL RATES
The Kaplan -Meier method indicated that patients who had positive staining for tumor cell VEGF-C had significantly worse survival rates than those who had negative staining. The median overall survival of 39 patients who had positive staining for tumor cell VEGF-C and 34 patients who had negative staining were 10.4 months (95% CI, 6.9 -13.9 months) and 28.5 months (95% CI, 12.6 -44.4 months), respectively (P ¼ 0.003) (Fig. 2) . One-year survival rates of patients who had positive staining for tumor cell VEGF-C was 38.5% (95% CI, 23.2 -53.7%), which was lower than patients who had negative staining (82.4%, 95% CI, 75.8 -88.9%) (P , 0.001). Three-and 5-year survival rate of patients who had positive staining for tumor cell VEGF-C Figure 1 . Vascular endothelial growth factor-C (VEGF-C) was observed in the cytoplasm of esophageal squamous cell carcinoma (Â200). 
DETERMINATION OF INDEPENDENT FACTORS AFFECTING PROGNOSIS
In univariate analysis by log-rank test, histological grade, pN, stage, lymphatic invasion and VEGF-C were significant prognostic factors (P ¼ 0.047, P ¼ 0.007, P ¼ 0.018, P ¼ 0.002 and P ¼ 0.003, respectively) ( Table 2) . A multivariate analysis was performed to evaluate the independent prognostic role of VEGF-C after adjusting for other significant covariates. All variables that significantly affected survival in univariate analysis were introduced into a Cox proportional hazard model (Table 3) . At the end of the stepwise process, VEGF-C expression maintained its independent prognostic influence on overall survival (P ¼ 0.0451), as well as pN status (P ¼ 0.0029).
DISCUSSION
Metastatic tumor spread through blood and/or lymphatic vessels occurs in most forms of human cancer, with regional pN often being the most important prognostic factor for cancer patients, including ESCC (37, 39) . Lymphatic metastases are the consequence of a complex metastatic process that includes: (i) dissemination of malignant cells from a primary tumor to the lymphatics; (ii) transport of tumor cells via the lymphatics to local lymph nodes; (iii) settling of tumor cells in the lymph nodes; and (iv) growth of metastatic tumors in the lymph nodes. Recent work in tumor lymphangiogenesis research has been focused on the VEGF family, especially VEGF-C. VEGF-C can regulate physiological and pathological blood vessel growth in vivo (40) . In addition, VEGF-C has been shown to regulate the growth of lymphatic vessels in various experimental models (41) . In a breast cancer model, VEGF-C promoted enhanced spreading of tumor cells to regional lymph nodes, and the degree of tumor lymphangiogenesis correlated with lymph node metastases (42) . VEGF-C, which may help to clarify the mechanism of lymphatic spread in patients with ESCC, was detected as a lymphangiogenetic factor in 1996 (4, 5) . In previous studies, 38.9 -76.5% of patients with esophageal cancer were shown by immunohistochemistry to express VEGF-C and 53.4% of our series were defined as positive (Table 4) . In this study, we observed that VEGF-C expression using immunohistochemistry was significantly associated with pN, as well as histological grade, pT and lymphatic invasion. The results of the present study did support previous reports, suggesting that VEGF-C plays a clinicopathological role in ESCC (26) ( Table 4 ). Several reports demonstrate that the expression of VEGFR-3, the specific receptor for VEGF-C, is also important in lymphatic spread in addition to VEGF-C expression in cancer cells in vitro or in lung, gastric and prostatic cancer and mesothelioma (4, 14, 19, 43) . Analysis of VEGFR-3 expression in combination with VEGF-C may help to clarify the mechanism involved in lymphatic spread of ESCC. It is one of the limitations of this study. Some clinical studies revealed that VEGF-C status in tumor cells was a significant prognostic predictor in gastric cancer (44) , colorectal cancer (45) , non-small cell lung cancer (46) and cervical cancer (23) . In ESCC, only a published study has assessed the prognostic significance (33); tumoral VEGF-C status was a significant prognostic factor in a univariate analysis, but a multivariate analysis failed to show a significance in a study (28) ; a univariate analysis failed to show that tumoral VEGF-C expression was a significant prognostic factor in four studies (34, 37, 47, 48) . The present study showed that high VEGF-C expression in tumor cells was a significant and independent factor to predict a poor prognosis in patients with ESCC (Table 4 ). There is a limitation to this study that the effect of VEGF-C on the lymphangiogenesis of the esophageal cancer was not analyzed in the present study using specific marker for lymphatic vessel endothelia (e.g. D2-40 monoclonal antibody) and did not know whether the marker correlated with the VEGF-C expression level. Pre-operative serum VEGF-C level.
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In conclusion, expression of VEGF-C is related to histological grade, pT, pN and lymphatic invasion, and is a prognostic indicator for ESCC.
